366 related articles for article (PubMed ID: 32192613)
1. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.
Salhotra VS; Sachdeva KS; Kshirsagar N; Parmar M; Ramachandran R; Padmapriyadarsini C; Patel Y; Mehandru L; Jaju J; Ponnuraja C; Gupta M; Kalaiselvan V; Shamim A; Khaparde S; Swaminathan S;
Indian J Tuberc; 2020 Jan; 67(1):29-37. PubMed ID: 32192613
[TBL] [Abstract][Full Text] [Related]
2. Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients.
Barvaliya SV; Desai MK; Panchal JR; Solanki RN
Indian J Tuberc; 2020 Apr; 67(2):222-230. PubMed ID: 32553316
[TBL] [Abstract][Full Text] [Related]
3. Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India.
Sarin R; Singla N; Vohra V; Singla R; Puri MM; Munjal S; Khalid UK; Myneedu VP; Kumar Verma A; Mathuria KK
Indian J Tuberc; 2019 Jan; 66(1):209-213. PubMed ID: 30878071
[TBL] [Abstract][Full Text] [Related]
4. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis.
Ndjeka N; Conradie F; Schnippel K; Hughes J; Bantubani N; Ferreira H; Maartens G; Mametja D; Meintjes G; Padanilam X; Variava E; Pym A; Pillay Y
Int J Tuberc Lung Dis; 2015 Aug; 19(8):979-85. PubMed ID: 26162365
[TBL] [Abstract][Full Text] [Related]
5. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.
Guglielmetti L; Le Dû D; Jachym M; Henry B; Martin D; Caumes E; Veziris N; Métivier N; Robert J;
Clin Infect Dis; 2015 Jan; 60(2):188-94. PubMed ID: 25320286
[TBL] [Abstract][Full Text] [Related]
6. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
Centers for Disease Control and Prevention
MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
[TBL] [Abstract][Full Text] [Related]
7. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
Franke MF; Khan P; Hewison C; Khan U; Huerga H; Seung KJ; Rich ML; Zarli K; Samieva N; Oyewusi L; Nair P; Mudassar M; Melikyan N; Lenggogeni P; Lecca L; Kumsa A; Khan M; Islam S; Hussein K; Docteur W; Chumburidze N; Berikova E; Atshemyan H; Atwood S; Alam M; Ahmed S; Bastard M; Mitnick CD
Am J Respir Crit Care Med; 2021 Jan; 203(1):111-119. PubMed ID: 32706644
[No Abstract] [Full Text] [Related]
8. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study.
Gao M; Gao J; Xie L; Wu G; Chen W; Chen Y; Pei Y; Li G; Liu Y; Shu W; Fan L; Wu Q; Du J; Chen X; Tang P; Xiong Y; Li M; Cai Q; Jin L; Mei Z; Pang Y; Li L
Clin Microbiol Infect; 2021 Apr; 27(4):597-602. PubMed ID: 32553880
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
Borisov SE; Dheda K; Enwerem M; Romero Leyet R; D'Ambrosio L; Centis R; Sotgiu G; Tiberi S; Alffenaar JW; Maryandyshev A; Belilovski E; Ganatra S; Skrahina A; Akkerman O; Aleksa A; Amale R; Artsukevich J; Bruchfeld J; Caminero JA; Carpena Martinez I; Codecasa L; Dalcolmo M; Denholm J; Douglas P; Duarte R; Esmail A; Fadul M; Filippov A; Davies Forsman L; Gaga M; Garcia-Fuertes JA; García-García JM; Gualano G; Jonsson J; Kunst H; Lau JS; Lazaro Mastrapa B; Teran Troya JL; Manga S; Manika K; González Montaner P; Mullerpattan J; Oelofse S; Ortelli M; Palmero DJ; Palmieri F; Papalia A; Papavasileiou A; Payen MC; Pontali E; Robalo Cordeiro C; Saderi L; Sadutshang TD; Sanukevich T; Solodovnikova V; Spanevello A; Topgyal S; Toscanini F; Tramontana AR; Udwadia ZF; Viggiani P; White V; Zumla A; Migliori GB
Eur Respir J; 2017 May; 49(5):. PubMed ID: 28529205
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
[TBL] [Abstract][Full Text] [Related]
11. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis in China.
Han X; Chen X; Sha W; Zhang X; Qiu L; Wang J; Wu G; Yao L; Lv Y; Zhang X; Zhou J; Tang S; Chu N
Int J Tuberc Lung Dis; 2020 Aug; 24(8):789-794. PubMed ID: 32912383
[No Abstract] [Full Text] [Related]
12. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement.
Parmar MM; Sachdeva KS; Dewan PK; Rade K; Nair SA; Pant R; Khaparde SD
PLoS One; 2018; 13(4):e0193903. PubMed ID: 29641576
[TBL] [Abstract][Full Text] [Related]
13. Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries.
Guglielmetti L; Hewison C; Avaliani Z; Hughes J; Kiria N; Lomtadze N; Ndjeka N; Setkina S; Shabangu A; Sikhondze W; Skrahina A; Veziris N; Furin J
Int J Tuberc Lung Dis; 2017 Feb; 21(2):167-174. PubMed ID: 28234080
[TBL] [Abstract][Full Text] [Related]
14. One Step Forward: Successful End-of-Treatment Outcomes of Patients With Drug-Resistant Tuberculosis Who Received Concomitant Bedaquiline and Delamanid in Mumbai, India.
Das M; Dalal A; Laxmeshwar C; Ravi S; Mamnoon F; Meneguim AC; Paryani R; Mathur T; Singh P; Mansoor H; Kalon S; Hossain FN; Lachenal N; Coutisson S; Ferlazzo G; Isaakidis P
Clin Infect Dis; 2021 Nov; 73(9):e3496-e3504. PubMed ID: 33079176
[TBL] [Abstract][Full Text] [Related]
15. Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
Migliori GB; Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Tiberi S; Tadolini M; Esposito S
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28178199
[TBL] [Abstract][Full Text] [Related]
16. Modeling the impact of bedaquiline treatment strategies on the multidrug-resistant tuberculosis burden in India.
Mehra M; Kambili C; Potluri R; Rhines A; Singh V; Thomas A
Int J Tuberc Lung Dis; 2017 Aug; 21(8):902-909. PubMed ID: 28786799
[TBL] [Abstract][Full Text] [Related]
17. Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis.
Perrineau S; Lachâtre M; Lê MP; Rioux C; Loubet P; Fréchet-Jachym M; Gonzales MC; Grall N; Bouvet E; Veziris N; Yazdanpanah Y; Peytavin G
Int J Tuberc Lung Dis; 2019 Jan; 23(1):99-104. PubMed ID: 30674381
[TBL] [Abstract][Full Text] [Related]
18. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
Pym AS; Diacon AH; Tang SJ; Conradie F; Danilovits M; Chuchottaworn C; Vasilyeva I; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; Van Baelen B; van Heeswijk RP; Dannemann B;
Eur Respir J; 2016 Feb; 47(2):564-74. PubMed ID: 26647431
[TBL] [Abstract][Full Text] [Related]
19. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis.
Liu Y; Gao J; Du J; Shu W; Wang L; Wang Y; Xue Z; Li L; Xu S; Pang Y
Int J Infect Dis; 2021 Jan; 102():392-396. PubMed ID: 33130209
[TBL] [Abstract][Full Text] [Related]
20. Reduced Susceptibility of Mycobacterium tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in China.
Liu Y; Gao M; Du J; Wang L; Gao J; Shu W; Wang Y; Xue Z; Li L; Pang Y
Clin Infect Dis; 2021 Nov; 73(9):e3391-e3397. PubMed ID: 32667984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
